Nebivolol Zidrium Teva Pharma (Nebivolol Hydrochloride)

Nebivolol is indicated for conditions within the cardiovascular disease spectrum where β1‑adrenergic blockade is therapeutic.

• Hypertension: lowers systemic blood pressure by reducing cardiac output and peripheral resistance.
• Heart failure: improves left ventricular ejection fraction and reduces symptoms of chronic heart failure.
• Chronic stable angina: may improve exercise capacity by decreasing heart rate and myocardial workload.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, decreasing heart rate and contractility, which reduces myocardial oxygen demand. In addition, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide‑mediated vasodilation and further lowering of peripheral vascular resistance. These actions also improve endothelial function and contribute to favorable remodeling of the cardiovascular system over long‑term therapy.

Nebivolol may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Headache: mild to moderate headache reported.
• Dizziness: sensation of light‑headedness, especially on standing.
• Fatigue: general tiredness or lack of energy.
• Nausea: occasional upset stomach.
• Bradycardia: slower than normal heart rate.
• Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: markedly low heart rate requiring medical attention.
• Heart block: atrioventricular conduction disturbances.
• Acute bronchospasm: difficulty breathing, particularly in patients with reactive airway disease.
• Hypotension: sudden drop in blood pressure causing faintness.
• Hepatic dysfunction: abnormal liver enzymes or hepatitis.
• Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing Nebivolol, clinicians should observe several precautionary measures to ensure safe use.

• Blood pressure monitoring: check baseline and periodic readings to avoid excessive hypotension.
• Cardiac function assessment: evaluate heart rate and conduction system, especially in patients with bradyarrhythmias.
• Liver impairment: use caution and consider dose adjustment in severe hepatic dysfunction.
• Renal impairment: adjust dosing in patients with significant renal insufficiency.
• Discontinuation: avoid abrupt cessation; taper gradually to prevent rebound hypertension.
• Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Nebivolol can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• Concomitant beta‑blockers: additive cardiac depression and severe bradycardia.
• Potent CYP2D6 inhibitors (e.g., paroxetine, quinidine): increase nebivolol plasma concentrations.
• Calcium‑channel blockers that affect AV node (verapamil, diltiazem): risk of excessive heart‑rate slowing.
• Other antihypertensives (e.g., ACE inhibitors, diuretics): may cause profound hypotension.
• Anti‑arrhythmic agents (e.g., amiodarone): heightened risk of conduction disturbances.

Moderate Interactions (Monitor Closely)

• NSAIDs: may attenuate antihypertensive effect.
• Diuretics: can exacerbate electrolyte imbalances and volume depletion.
• Insulin or oral hypoglycemics: beta‑blockade may mask hypoglycemia symptoms.
• Antidepressants (e.g., sertraline): potential for modest increase in nebivolol levels.
• Lipid‑lowering agents (e.g., statins): monitor for rare myopathy when combined with high‑dose therapy.